Pulmonary hypertension (PH) is a complex and progressive condition characterized by elevated pulmonary arterial pressure and secondary right ventricular failure. The disease has a multifactorial etiology, making it a challenge for clinicians. This article provides an overview of the fundamentals of PH, aiming to enhance understanding and facilitate better patient management.
PH is primarily a disorder of the small pulmonary arteries. Vasoconstriction, vascular remodeling, and thrombosis in situ contribute to the elevated pulmonary vascular resistance. As pressure builds in the pulmonary arteries, the right ventricle must work harder, leading to hypertrophy and eventual right heart failure.
PH often presents with non-specific symptoms such as dyspnea, fatigue, and chest pain. This can delay diagnosis and intervention. Echocardiography is a key tool in the initial evaluation and suspicion of PH, but right heart catheterization remains the gold standard for diagnosis, providing direct, accurate measurements of pulmonary arterial pressure.
The World Health Organization (WHO) classifies PH into five groups based on etiology. This classification guides treatment, which ranges from general measures and supportive therapy to advanced targeted treatments. Treatments aim to relieve symptoms, slow disease progression, and improve quality of life. Early recognition and appropriate treatment of PH can significantly improve patient outcomes.
PH management requires a multidisciplinary approach. Cardiologists, pulmonologists, rheumatologists, and other specialists often need to collaborate for optimal patient management. Each member of the team plays a critical role in diagnosing, managing, and monitoring the patient's condition.
Understanding the intricacies of PH is crucial for effective patient management. Clinicians need to be aware of the pathophysiology, clinical presentation, diagnostic methods, classification, treatment options, and the importance of a multidisciplinary approach in managing this complex condition. Continuous research and education are needed to improve the prognosis and quality of life for patients with PH.
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation